论文部分内容阅读
[目的]研究人类组织激肽释放酶(kallikrein,KLK)6蛋白在卵巢上皮性癌组织及腹膜后淋巴结中的表达,探讨其在卵巢上皮性癌中的临床意义。[方法]回顾性分析卵巢肿瘤患者的临床病理资料,采用免疫组化检测72例卵巢癌、16例卵巢交界性肿瘤、20例良性卵巢上皮性肿瘤组织KLK6蛋白的表达;并采用配对设计研究KLK6蛋白在卵巢癌患者腹膜后淋巴结中的表达,探讨KLK6在卵巢上皮性癌发生、发展中的作用。[结果]KLK6在卵巢癌及交界性卵巢肿瘤中的阳性表达分别为52.8%(38/72)、25.0%(4/16),均显著强于良性上皮性卵巢肿瘤15.0%(3/20)(P<0.05)。KLK6阳性表达与卵巢癌的临床分期、组织学分级及淋巴结转移有关(P<0.05),与组织学类型无相关性(P>0.05);KLK6在卵巢癌原发灶与腹膜后转移淋巴结组织中的表达呈正相关(r=8.91,P=0.003);KLK6阳性与阴性患者的平均生存时间分别为25.9个月和49.2个月(P<0.05)。[结论]KLK6高表达可能在卵巢上皮性癌的发生发展中起潜在作用,KLK6可能与卵巢上皮性癌的浸润、转移有关,KLK6是卵巢癌的不良预后因素之一。
[Objective] To investigate the expression of human kallikrein (KLK) 6 protein in epithelial ovarian cancer tissues and retroperitoneal lymph nodes and to explore its clinical significance in epithelial ovarian cancer. [Methods] The clinical and pathological data of ovarian cancer patients were retrospectively analyzed. The expression of KLK6 protein in 72 cases of ovarian cancer, 16 cases of ovarian borderline tumor and 20 cases of benign ovarian epithelial tumor was detected by immunohistochemistry. The paired design was used to study the expression of KLK6 Protein expression in the retroperitoneal lymph nodes of ovarian cancer patients and explore the role of KLK6 in the occurrence and development of epithelial ovarian cancer. [Results] The positive rates of KLK6 in ovarian cancer and borderline ovarian tumors were 52.8% (38/72) and 25.0% (4/16), respectively, which were significantly higher than those in benign epithelial ovarian tumors (15.0%, 3/20) (P <0.05). The positive expression of KLK6 was correlated with the clinical stage, histological grade and lymph node metastasis (P <0.05), but not with the histological type (P> 0.05). The expression of KLK6 in primary ovarian cancer and retroperitoneal lymph node (R = 8.91, P = 0.003). The average survival time of KLK6 positive and negative patients were 25.9 months and 49.2 months (P <0.05), respectively. [Conclusion] The high expression of KLK6 may play a role in the occurrence and development of epithelial ovarian cancer. KLK6 may be involved in the invasion and metastasis of epithelial ovarian cancer. KLK6 is one of the adverse prognostic factors of ovarian cancer.